(2R,3R)-2,3-Bis-[(Z)-3-(4-methoxycarbonyloxy-phenyl)-acryloyloxy]-succinic acid | 222320-75-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (2R,3R)-2,3-Bis-[(Z)-3-(4-methoxycarbonyloxy-phenyl)-acryloyloxy]-succinic acid
• CAS: 222320-75-4
• 化学式: C₂₆H₂₂O₁₄
• 分子量: 558.452
• InChiKey: QSEJPJBLDBTVHN-FGZHOGPDSA-N

物化性质

• 沸点：
  753.0±60.0 °C(predicted)
• 密度：
  1.457±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  40.0
• 可旋转键数：
  11.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  198.26
• 氢给体数：
  2.0
• 氢受体数：
  12.0

反应信息

• 作为反应物：
  描述：

  (2R,3R)-2,3-Bis-[(Z)-3-(4-methoxycarbonyloxy-phenyl)-acryloyloxy]-succinic acid 在 ammonium hydroxide 作用下， 以 甲醇 为溶剂， 以89%的产率得到bis(4-hydroxycinnamoyl)-L-tartaric acid
  参考文献：
  名称：

  FR258900酒石酸类似物的合成及其作为糖原磷酸化酶抑制剂的评价

  摘要：

  合成了二-O-肉桂酸化，-p-香豆酰化和-阿魏酸化的d-，l-和内消旋酒石酸作为天然产物FR258900的类似物，FR258900是一种具有体内抗高血糖活性的糖原磷酸化酶（GP）抑制剂。新化合物在低微摩尔范围内抑制兔肌肉GP，并与酶的变构位点结合。最好的抑制剂是2,3-二-O-阿魏酰基内消旋酒石酸，抗AMP的K i值为2.0μM （竞争性），抗葡萄糖-1-磷酸的K i值为3.36μM （非竞争性）。

  DOI：

  10.1016/j.bmcl.2013.01.042
• 作为产物：
  描述：

  p-coumaric acid 在 吡啶 、 氯化亚砜 、 苯甲醚 、 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 6.0h， 生成 (2R,3R)-2,3-Bis-[(Z)-3-(4-methoxycarbonyloxy-phenyl)-acryloyloxy]-succinic acid
  参考文献：
  名称：

  FR258900酒石酸类似物的合成及其作为糖原磷酸化酶抑制剂的评价

  摘要：

  合成了二-O-肉桂酸化，-p-香豆酰化和-阿魏酸化的d-，l-和内消旋酒石酸作为天然产物FR258900的类似物，FR258900是一种具有体内抗高血糖活性的糖原磷酸化酶（GP）抑制剂。新化合物在低微摩尔范围内抑制兔肌肉GP，并与酶的变构位点结合。最好的抑制剂是2,3-二-O-阿魏酰基内消旋酒石酸，抗AMP的K i值为2.0μM （竞争性），抗葡萄糖-1-磷酸的K i值为3.36μM （非竞争性）。

  DOI：

  10.1016/j.bmcl.2013.01.042

文献信息

• Structure−Activity Relationships:  Analogues of the Dicaffeoylquinic and Dicaffeoyltartaric Acids as Potent Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and Replication
  作者：Peter J. King、Guoxiang Ma、Wenfang Miao、Qi Jia、Brenda R. McDougall、Manfred G. Reinecke、Chris Cornell、Jean Kuan、Tracey R. Kim、W. Edward Robinson

  DOI：10.1021/jm9804735

  日期：1999.2.1

  The dicaffeoylquinic acids (DCQAs) and dicaffeoyltartaric acids (DCTAs) are potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase. They also inhibit HIV-1 replication at nontoxic concentrations; Since integrase is an excellent target for anti-HIV therapy, structure-activity relationships were employed to synthesize compounds with: (1) improved potency against HIV-1 integrase, (2) improved anti-HIV effect in tissue culture, and (3) increased selectivity as indicated by low cellular toxicity. Thirty-four analogues of the DCTAs and DCQAs were synthesized and tested for cell toxicity, anti-HIV activity, and inhibition of HIV-1 integrase. Seventeen of the 34 analogues had potent activity against HIV-1 integrase ranging from 0.07 to >10 mu M. Seventeen analogues that were synthesized or purchased had no inhibitory activity against integrase at concentrations of 25 mu M. Of the biologically active analogues, 7 of the 17 inhibited HIV replication at nontoxic concentrations. The most potent compounds were D-chicoric acid, meso-chicoric acid, bis(3,4-dihydroxydihydrocinnamoyl)-L-tartaric acid, digalloyl-L-tartaric acid, bis(3,4-dihydroxybenzoyl)-L-tartaric acid, dicaffeoylglyceric acid, and bis(3,4-dihydroxyphenylacetyl)-L-tartaric acid. Anti-HIV activity of the active compounds in tissue culture ranged from 35 to 0.66 mu M. Structure-activity relationships demonstrated that biscatechol moieties were absolutely required for inhibition of integrase, while at least one free carboxyl group was required for anti-HIV activity. These data demonstrate that analogues of the DCTAs and the DCQAs can be synthesized which have improved activity against HIV integrase.